公司概述
Qiagen N.V. operates within the healthcare sector, specifically serving the diagnostics and research industry by providing sample to insight solutions that globally transform biological samples into molecular insights for genotyping and gene analysis. The company generates substantial scale with a market capitalization of $8.05 billion and annual revenue reaching $2.09 billion over the trailing twelve months, supported by a workforce of 5,654 employees. This valuation and revenue profile positions Qiagen as a significant player in the specialized field of nucleic acid stabilization and purification kits, as well as manual and automated processing technologies. The market cap figure reflects investor confidence in the company's ability to deliver consistent molecular insights, while the revenue base of $2.09 billion underscores its established footprint in a high-barrier-to-entry market where quality and reliability are paramount for scientific research and clinical applications.
财务健康
The company reports trailing twelve-month revenue of $2.09 billion with corresponding net income of $424.88 million and EBITDA of $728.29 million. The gap between the $2.09 billion revenue and $424.88 million net income reveals a robust cost structure where operating expenses and taxes absorb approximately 79.7% of total revenue before arriving at the bottom line. Free cash flow stands at $257.10 million, indicating that after capital expenditures, the company retains significant cash liquidity to fund operations, pursue acquisitions, or return capital to shareholders without relying on external financing. The gross margin is 66.4%, demonstrating high pricing power and efficient manufacturing or supply chain costs typical of diagnostic consumables. Operating margin reaches 27.4%, while profit margin sits at 20.3%, showing that the company effectively converts a large portion of its operating earnings into actual profit after interest and taxes. On the balance sheet, total cash holdings of $1.10 billion are lower than total debt of $1.83 billion, resulting in a debt-to-equity ratio of 48.56% which suggests a leveraged position rather than a conservative one. Despite the leverage, the current ratio of 3.90 indicates strong short-term liquidity, as current assets are nearly four times the value of current liabilities, ensuring the ability to meet short-term obligations comfortably. Return on Equity is 11.6% and return on assets is 5.8%, metrics that reveal management's effectiveness in generating returns on shareholder capital and utilizing the entire asset base to drive earnings.
估值评估
The trailing twelve-month P/E ratio is 19.15, while the forward P/E is 14.14, implying that the market expects earnings growth that would justify a lower multiple in the future compared to historical performance. The price-to-book ratio stands at 2.13, indicating that the market values the company at a significant premium of roughly 113% over its net asset book value, reflecting intangible assets like intellectual property and brand strength. Alternative valuation metrics include a price-to-sales ratio of 3.85 and an EV/EBITDA of 12.06, suggesting that investors are willing to pay a moderate multiple relative to sales and cash generation capabilities. The stock trades within a 52-week range bounded by a high of $57.82 and a low of $38.13, meaning the current price sits somewhere between these extremes with a beta of 0.71. This beta value indicates that the stock exhibits lower volatility relative to the broader market, moving at approximately 29% less intensity than the market average during periods of fluctuation.
Growth & Income
Revenue growth over the last year is 3.7%, whereas earnings growth accelerates significantly at 21.9%, implying that earnings are expanding much faster than top-line sales due to margin expansion or cost efficiencies. The company offers a dividend yield of 0.7% with a payout ratio of 12.9%, a low payout ratio that suggests dividends are highly sustainable and leave ample earnings for reinvestment or debt reduction. Given the low payout ratio, the company retains the majority of its earnings to fund research, development, and operational growth rather than maximizing immediate dividend returns. Overall, the growth and income profile presents a balance of steady revenue expansion, accelerating earnings growth, and a conservative yet sustainable approach to shareholder returns through modest dividends.